NCT05303220View on ClinicalTrials.gov

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Branebrutinib

Specified dose on specified days

DRUG

Placebo

Specified Dose on specified days

Trial Locations (1)

33136

Local Institution - 0001, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05303220 - A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants | Biotech Hunter | Biotech Hunter